Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway.
VanCleave A, Palmer M, Fang F, Torres H, Rodezno T, Li Q, Fuglsby K, Evans C, Afeworki Y, Ross A, Rao P, Leiferman P, Zheng S, Houghton P, Tao J.
VanCleave A, et al. Among authors: li q.
Oncotarget. 2020 Jul 7;11(27):2597-2610. doi: 10.18632/oncotarget.27611. eCollection 2020 Jul 7.
Oncotarget. 2020.
PMID: 32676162
Free PMC article.